A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs ADXS 31164 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer; Osteosarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Advaxis
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2016 Status changed from active, no longer recruiting to recruiting.
- 18 Feb 2016 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018, according to ClinicalTrials.gov record.